Disc Medicine, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
Disc Medicine, Inc. (IRON) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of 1.30% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-02-26
- Disc Medicine, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2025 was 1.30%, a 0.00% change from fiscal 2024.
- Disc Medicine, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was 1.30%, a 0.00% change from fiscal 2023.
- Disc Medicine, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was 1.30%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month |
|---|---|
| 2025-12-31 | 1.30% 10-K · filed 2026-02-26 |
| 2024-12-31 | 1.30% 10-K · filed 2026-02-26 |
| 2023-12-31 | 1.30% 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |